Biote Reaffirms Revenue Targets for 2026, Addresses Supply Chain Restoration

Biote, a health and wellness organization, recently confirmed its financial expectations for the year 2026, projecting revenues to surpass $190 million. This information was shared by Seeking Alpha, highlighting the company's continued confidence in its long-term growth strategy despite current operational challenges. The company is actively working to restore the full availability of its Asteria line of products, which has faced recent supply issues. Biote aims to have these supply chain matters resolved and product availability fully reinstated by the conclusion of the second quarter of the current fiscal year. Leadership at Biote has communicated that the initial impact from these supply chain interruptions was largely felt in the closing weeks of the first quarter, extending into the beginning of the second quarter. These disruptions primarily affected the company's bio-identical hormone replacement therapy (BHRT) pellets, a key component of their offerings. Despite these short-term hurdles, the company emphasized that its overall market strategy remains robust. Biote is focused on expanding its network of certified practitioners and enhancing its product development pipeline. The company believes these efforts will underpin sustained growth and help achieve its ambitious revenue targets. The commitment to its 2026 financial forecast, as reported by Seeking Alpha, underscores Biote's belief that the current supply issues are temporary and will not significantly impede its long-term trajectory. The organization has indicated that ongoing measures are in place to prevent similar disruptions in the future, aiming to strengthen its distribution and manufacturing resilience.